Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17482381 | 0.89 | CA2 (0.43) | L3MBTL1NPC1RAB9AMAOANOTUM | |
| SCHEMBL22358511 | 0.86 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9ACA1 | |
| SCHEMBL28433534 | 0.85 | KDM4C (0.46) | KDM4CL3MBTL1NPC1RAB9ARXRA | |
| SCHEMBL22358510 | 0.85 | KDM4C (0.42) | KDM4CL3MBTL1NPC1RAB9ARXRA | |
| SCHEMBL22859609 | 0.85 | KDM4C (0.44) | KDM4CL3MBTL1NPC1RAB9ACA1 | |
| SCHEMBL24858499 | 0.82 | KDM4C (0.40) | KDM4CL3MBTL1NPC1RAB9ARXRA | |
| SCHEMBL20857100 | 0.80 | SPHK1 (0.42) | KDM4CL3MBTL1NPC1RAB9ACA1 | |
| SCHEMBL27398359 | 0.80 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9ANOTUM | |
| SCHEMBL20047076 | 0.78 | CA1 (0.43) | L3MBTL1NOTUMCA1CA2CA9 | |
| SCHEMBL20857082 | 0.78 | RXRA (0.48) | CA1CA2CA9RXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-114222590-A | Compositions, devices and methods for factor VII therapy | 西吉隆医疗股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113840620-A | Compositions, devices and methods for treating fabry disease | 西吉隆医疗股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3687580-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | Sigilon Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111372612-A | Methods, compositions, and implantable elements comprising viable cells | 西吉隆医疗股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | GLA, GAA, GBA1 | KDM4C 4246/4885L3MBTL1 4461/4885NPC1 48/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | KDM4C 4682/4885L3MBTL1 2803/4885NPC1 343/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | KDM4C 4682/4885L3MBTL1 2803/4885NPC1 343/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | KDM4C 4682/4885L3MBTL1 2803/4885NPC1 343/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | KDM4C 4413/4885L3MBTL1 3567/4885NPC1 1419/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | KDM4C 2986/4885L3MBTL1 1756/4885NPC1 2031/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | KDM4C 4124/4885L3MBTL1 3311/4885NPC1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.